EGFR inhibitors in NSCLC and the role of biomarkers for selection of patients [electronic resource] / Fred R. Hirsch.
Material type:
FilmSeries: Henry Stewart talksBiomedical & life sciences collection. Cancer therapy : latest thinking in efficacy and toxicity: Publisher: London : Henry Stewart Talks, 2009Description: 1 online resource (1 streaming video file (36 min.) : color, sound)Subject(s): Biomarkers | Neoplasms -- complications | Neoplasms -- therapy | Receptor, Epidermal Growth Factor -- antagonists & inhibitorsOnline resources: Click here to access online | Series Animated audio-visual presentation with synchronized narration.
Title from title frames.
Contents: USAEGFR TKIs in 2nd /3rd line therapy -- Phase II activity of EGFR TKIs in unselected NSCLC -- BR.21 study design and overall survival -- Forest plot of survival by subsets -- Is there a survival advantage for male smokers with squamous-cell carcinoma? -- Trials comparing Gefitinib to Docetaxel -- SIGN trial -- RECIST study -- INTEREST study -- EGFR inhibitors in first line therapy -- Randomized Trials of CT+/- active targeted Rx -- Maintenance of Gefitinib WJTOG 0203 -- Cetuximab in NSCLC -- EGFR interacting molecules.
Access restricted to subscribers.
Mode of access: World Wide Web.